Key facts
- GeneCradle’s last known valuation is $287.8M (Feb 2022).
- It has raised $61.0M; the latest was Later Stage VC in Feb 2025.
- Notable investors include Shenzhen Capital Group, Oriental Fortune Capital, YuanBio Venture Capital, CASH Capital, Cherami Investment Group — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for GeneCradle
- ·The full record, as it builds
Funding rounds
No funding rounds for GeneCradle are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GeneCradle
Developer of gene therapy drugs intended to treat rare diseases. The company's drugs are mediated by recombinant adeno-associated virus vector (rAAV) delivery technology to create new drugs in the fields of hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal diseases, hereditary diseases, and ophthalmic diseases, providing healthcare professionals with a product production guarantee that meets good manufacturing practices (GMP) requirements for the development of multi-variety and multi-field genetic medicines.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Website
- bj-genecradle.com/
- Ownership
- Privately Held (backing)
GeneCradle doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GeneCradle shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GeneCradle in its N-PORT filings yet. We sweep new filings monthly.